Business Context and Reporting Period
This Form 8-K Current Report was filed by Skye Bioscience, Inc. on February 14, 2023. The filing addresses corporate governance changes, specifically the departure of a director and the election of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
- Director Resignation: Bobby Rai resigned from the Board of Directors and the Nominating and Corporate Governance Committee on February 14, 2023. The resignation was to focus on other commitments and was not the result of any disagreement with the Company.
- Director Election: Dr. Deborah Charych, Ph.D., was elected to the Board on February 14, 2023, to fill the vacancy created by Mr. Rai's resignation.
Compensation and Governance Details
Dr. Charych's appointment includes the following compensatory arrangements:
- Annual Cash Compensation: $40,000 for service on the Board.
- Stock Options: Grant of options to purchase 250,000 shares of common stock at the fair market value per share as of the grant date.
- Vesting Schedule: Options vest in equal monthly installments over one year, contingent on continued service.
- Indemnification: Dr. Charych entered into the Company's standard indemnification agreement.
Investor Verification Checklist
- Verify the effective date of Dr. Charych's service and the specific vesting schedule of the 250,000 stock options.
- Confirm the current composition of the Board of Directors following Mr. Rai's departure.
- Review the attached press release (Exhibit 99.1) for additional context on Dr. Charych's background and qualifications.
- Check subsequent filings for any changes to the Board's committee assignments.